Targeting EGFR Exon 20 Insertions in NSCLC: Current and Future Prospects

Program Overview

This activity has been designed to meet the educational needs of healthcare providers involved in the management of patients with advanced non-small cell lung cancer (NSCLC).

Credit Expired

1.00 CE Credit(s)

Expires: September 9, 2021

Target Audience

This activity is intended for medical oncology, pathology, and pulmonology clinicians attending the virtual IASLC 2021 World Conference on Lung Cancer meeting and who are involved in the management of patients with advanced non-small cell lung cancer (NSCLC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

Analyze the predictive/prognostic significance of EGFR exon 20 insertion
mutations in non-small cell lung cancer (NSCLC)
Apply optimal diagnostic strategies for identifying NSCLC with EGFR
exon 20 insertions
Assess clinical trial data regarding new and emerging treatment options
for advanced NSCLC with EGFR exon 20 insertions
Employ appropriate techniques to manage adverse events associated
with EGFR inhibition

Activity Faculty

Professor Tony S.K. Mok, BMSc, MD, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO (Chair)

Li Shu Fan Medical Foundation Professor, Clinical Oncology
The Chinese University of Hong Kong
Hong Kong, China

Shirish M. Gadgeel, MD

Chief, Division of Hematology and Oncology
Department of Internal Medicine
Henry Ford Cancer Institute/Henry Ford Health System
Detroit, MI

Antonio Passaro, MD, PhD

Medical Oncologist, Division of Thoracic Oncology
European Institute of Oncology
Milan, Italy

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Featured RMEI CE Activities

Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care

Closing the Gap: Personalized Approaches to Cervical Cancer Screening and Treatment

Privacy | Terms of Use